Notice of Results

RNS Number : 0096M

Syncona Limited

19 May 2022

 

Syncona Limited

Notice of Final Results

19 May 2022

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, will announce its final results for the year ended 31 March 2022 on Thursday 16 June 2022.

Syncona will host a webcast and conference call the same day at 9.00am BST, with an opportunity to ask questions via the conference call line. The webcast will be available on the Company's website at https://www.synconaltd.com/ or via this link. Alternatively, please contact [e-mail] for details of the conference call.

[ENDS]

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: [phone]

FTI Consulting

Ben Atwell / Julia Bradshaw / Tim Stamper

Tel: [phone]

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

END

 

 

NORBKFBBABKDKPD